CRO Novotech springboards into US
Tuesday, 15 June, 2004
Australian CRO Novotech is setting up operations in the US to take advantage of the clinical trials opportunities offered there.
"There is a natural ceiling in Australia for the size of clinical trials, due to our [small] population. We're expanding offshore so that we can do larger trials -- primarily in the US," said CEO Alek Safarian at last week's BIO 2004 conference at San Francisco.
While the company will be competing with other US CROs for clinical trials, Safarian said he believed Novotech would have an advantage in being able to leverage its Australian experience and access.
In the last three years, Novotech has worked primarily with US-based biotech companies and pharma companies, including Angiogenix and OSI Pharmaceuticals, as well as UK-based SkyePharma.
Safarian said Novotech would have its US-based service on the ground by the end of this year. "We already have business development here, but we need operations in the US," he said.
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
